The dose-dependent macular thickness changes assessed by FD-OCT in patients with retinitis pigmentosa treated with ciliary neurotrophic factor

Suman Pilli, Robert Zawadzki, David G. Telander

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

PURPOSE: To evaluate the effect of intravitreal ciliary neurotrophic factor (CNTF) implant on mean macular thickness (MMT) in eyes with retinitis pigmentosa using high-resolution Fourier domain optical coherence tomography imaging. METHODS: A cohort of 8 patients (CNTF-3: n = 5; CNTF-4: n = 3) enrolled in Neurotech sponsored Phase 2 clinical trial underwent Fourier domain optical coherence tomography imaging. A ≥3% change in MMT from baseline or fellow eye was considered as a measurable change. RESULTS: Two patients enrolled in the CNTF-3 study received low-dose implant. At 18 months, a change in MMT from -4.47 μm to 6 μm from baseline was noted. Six patients received high-dose implant (CNTF-3: n = 3; CNTF-4: n = 3). In CNTF-3 group, 1 eye showed an increase in MMT by 19.25 μm (+7.6%) from baseline at 18 months. In CNTF-4 group, 1 eye had an increase in MMT of 27.08 μm (+11%) from baseline at 30 months; second eye had increase in MMT of 31.36 μm (+12%) from contralateral eye. Amongst these 3 responsive high-dose implant eyes, overall thickening of the retina could not be attributed to any specific retinal layer. CONCLUSION: A heterogeneous dose-dependent response on MMT was noted in eyes treated using intravitreal CNTF implant for retinitis pigmentosa. We recommend corroboration of our findings with Neurotech sponsored clinical trial results.

Original languageEnglish (US)
Pages (from-to)1384-1390
Number of pages7
JournalRetina
Volume34
Issue number7
DOIs
StatePublished - Jan 1 2014

Fingerprint

Ciliary Neurotrophic Factor
Retinitis Pigmentosa
Optical Coherence Tomography
Clinical Trials
Retina

Keywords

  • ciliary neurotrophic factor
  • encapsulated cell implant
  • Fourier domain optical coherence tomography
  • mean macular thickness
  • retinitis pigmentosa

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The dose-dependent macular thickness changes assessed by FD-OCT in patients with retinitis pigmentosa treated with ciliary neurotrophic factor. / Pilli, Suman; Zawadzki, Robert; Telander, David G.

In: Retina, Vol. 34, No. 7, 01.01.2014, p. 1384-1390.

Research output: Contribution to journalArticle

@article{bf6e6097c3944777b54dee57ac9ef43c,
title = "The dose-dependent macular thickness changes assessed by FD-OCT in patients with retinitis pigmentosa treated with ciliary neurotrophic factor",
abstract = "PURPOSE: To evaluate the effect of intravitreal ciliary neurotrophic factor (CNTF) implant on mean macular thickness (MMT) in eyes with retinitis pigmentosa using high-resolution Fourier domain optical coherence tomography imaging. METHODS: A cohort of 8 patients (CNTF-3: n = 5; CNTF-4: n = 3) enrolled in Neurotech sponsored Phase 2 clinical trial underwent Fourier domain optical coherence tomography imaging. A ≥3{\%} change in MMT from baseline or fellow eye was considered as a measurable change. RESULTS: Two patients enrolled in the CNTF-3 study received low-dose implant. At 18 months, a change in MMT from -4.47 μm to 6 μm from baseline was noted. Six patients received high-dose implant (CNTF-3: n = 3; CNTF-4: n = 3). In CNTF-3 group, 1 eye showed an increase in MMT by 19.25 μm (+7.6{\%}) from baseline at 18 months. In CNTF-4 group, 1 eye had an increase in MMT of 27.08 μm (+11{\%}) from baseline at 30 months; second eye had increase in MMT of 31.36 μm (+12{\%}) from contralateral eye. Amongst these 3 responsive high-dose implant eyes, overall thickening of the retina could not be attributed to any specific retinal layer. CONCLUSION: A heterogeneous dose-dependent response on MMT was noted in eyes treated using intravitreal CNTF implant for retinitis pigmentosa. We recommend corroboration of our findings with Neurotech sponsored clinical trial results.",
keywords = "ciliary neurotrophic factor, encapsulated cell implant, Fourier domain optical coherence tomography, mean macular thickness, retinitis pigmentosa",
author = "Suman Pilli and Robert Zawadzki and Telander, {David G.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/IAE.0000000000000064",
language = "English (US)",
volume = "34",
pages = "1384--1390",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - The dose-dependent macular thickness changes assessed by FD-OCT in patients with retinitis pigmentosa treated with ciliary neurotrophic factor

AU - Pilli, Suman

AU - Zawadzki, Robert

AU - Telander, David G.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - PURPOSE: To evaluate the effect of intravitreal ciliary neurotrophic factor (CNTF) implant on mean macular thickness (MMT) in eyes with retinitis pigmentosa using high-resolution Fourier domain optical coherence tomography imaging. METHODS: A cohort of 8 patients (CNTF-3: n = 5; CNTF-4: n = 3) enrolled in Neurotech sponsored Phase 2 clinical trial underwent Fourier domain optical coherence tomography imaging. A ≥3% change in MMT from baseline or fellow eye was considered as a measurable change. RESULTS: Two patients enrolled in the CNTF-3 study received low-dose implant. At 18 months, a change in MMT from -4.47 μm to 6 μm from baseline was noted. Six patients received high-dose implant (CNTF-3: n = 3; CNTF-4: n = 3). In CNTF-3 group, 1 eye showed an increase in MMT by 19.25 μm (+7.6%) from baseline at 18 months. In CNTF-4 group, 1 eye had an increase in MMT of 27.08 μm (+11%) from baseline at 30 months; second eye had increase in MMT of 31.36 μm (+12%) from contralateral eye. Amongst these 3 responsive high-dose implant eyes, overall thickening of the retina could not be attributed to any specific retinal layer. CONCLUSION: A heterogeneous dose-dependent response on MMT was noted in eyes treated using intravitreal CNTF implant for retinitis pigmentosa. We recommend corroboration of our findings with Neurotech sponsored clinical trial results.

AB - PURPOSE: To evaluate the effect of intravitreal ciliary neurotrophic factor (CNTF) implant on mean macular thickness (MMT) in eyes with retinitis pigmentosa using high-resolution Fourier domain optical coherence tomography imaging. METHODS: A cohort of 8 patients (CNTF-3: n = 5; CNTF-4: n = 3) enrolled in Neurotech sponsored Phase 2 clinical trial underwent Fourier domain optical coherence tomography imaging. A ≥3% change in MMT from baseline or fellow eye was considered as a measurable change. RESULTS: Two patients enrolled in the CNTF-3 study received low-dose implant. At 18 months, a change in MMT from -4.47 μm to 6 μm from baseline was noted. Six patients received high-dose implant (CNTF-3: n = 3; CNTF-4: n = 3). In CNTF-3 group, 1 eye showed an increase in MMT by 19.25 μm (+7.6%) from baseline at 18 months. In CNTF-4 group, 1 eye had an increase in MMT of 27.08 μm (+11%) from baseline at 30 months; second eye had increase in MMT of 31.36 μm (+12%) from contralateral eye. Amongst these 3 responsive high-dose implant eyes, overall thickening of the retina could not be attributed to any specific retinal layer. CONCLUSION: A heterogeneous dose-dependent response on MMT was noted in eyes treated using intravitreal CNTF implant for retinitis pigmentosa. We recommend corroboration of our findings with Neurotech sponsored clinical trial results.

KW - ciliary neurotrophic factor

KW - encapsulated cell implant

KW - Fourier domain optical coherence tomography

KW - mean macular thickness

KW - retinitis pigmentosa

UR - http://www.scopus.com/inward/record.url?scp=84903316903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903316903&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000064

DO - 10.1097/IAE.0000000000000064

M3 - Article

C2 - 24368307

AN - SCOPUS:84903316903

VL - 34

SP - 1384

EP - 1390

JO - Retina

JF - Retina

SN - 0275-004X

IS - 7

ER -